China is conducting more clinical drug trials than the U.S., but still falls short when it comes to quality and the commercial reach of its biomedical science, according to a survey of U.S. industry and academic leaders.
The poll, which was lead by the Cure Innovation Index, found that China was leading when it comes to clinical development and supply chain infrastructure.
Meanwhile, the U.S. was found to have advantages in capital formation and commercialization, technology transfer and talent.
Out of 117 respondents, 72% said China's biomedical sector is improving faster than the U.S., while 85% said the U.S. lead will last 10 years or less.
Moreover, 74% said declining U.S. federal research funding has been the biggest threat to biomedical leadership rather than any single competitive move from China, while 76% forecasted more research and development will move outside the U.S. if the current trends continue.